Literature DB >> 27749396

Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease.

Rainer von Coelln1, Lisa M Shulman.   

Abstract

PURPOSE OF REVIEW: Recent studies on clinical, genetic and pathological heterogeneity of Parkinson disease have renewed the old debate whether we should think of Parkinson disease as one disease with variations, or as a group of independent diseases that happen to present with similar phenotypes. Here, we provide an overview of where the debate is coming from, and how recent findings in clinical subtyping, genetics and clinico-pathological correlation have shaped this controversy over the last few years. RECENT
FINDINGS: New and innovative clinical diagnostic criteria for Parkinson disease have been proposed and await validation. Studies using functional imaging or wearable biosensors, as well as biomarker studies, provide new support for the validity of the traditional clinical subtypes of Parkinson disease (tremor-dominant versus akinetic-rigid or postural instability/gait difficulty). A recent cluster analysis (as unbiased data-driven approach to subtyping) included a wide spectrum of nonmotor variables, and showed correlation of the proposed subtypes with disease progression in a longitudinal analysis. New genetic factors contributing to Parkinson disease susceptibility continue to be identified, including rare mutations causing monogenetic disease, common variants with small effect size and risk factors (like mutations in the gene for glucocerebrosidase) that fall in between the two other categories. Recent studies show some limited correlation between genetic factors and clinical heterogeneity. Despite some variations in patterns of pathology, Lewy bodies are still the hallmark of Parkinson disease, including the vast majority of genetic subgroups.
SUMMARY: Evidence of clinical, genetic and pathological heterogeneity of Parkinson disease continues to emerge, but clearly defined subtypes that hold up in more than one of these domains remain elusive. For research to identify such subtypes, splitting is likely the way forward; until then, for clinical practice, lumping remains the more pragmatic approach.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27749396     DOI: 10.1097/WCO.0000000000000384

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  23 in total

1.  Gray Matter Abnormalities in Idiopathic Parkinson's Disease: Evaluation by Diffusional Kurtosis Imaging and Neurite Orientation Dispersion and Density Imaging.

Authors:  Koji Kamagata; Andrew Zalesky; Taku Hatano; Ryo Ueda; Maria Angelique Di Biase; Ayami Okuzumi; Keigo Shimoji; Masaaki Hori; Karen Caeyenberghs; Christos Pantelis; Nobutaka Hattori; Shigeki Aoki
Journal:  Hum Brain Mapp       Date:  2017-05-04       Impact factor: 5.038

Review 2.  Critical Roles of Glutaredoxin in Brain Cells-Implications for Parkinson's Disease.

Authors:  Olga Gorelenkova Miller; John J Mieyal
Journal:  Antioxid Redox Signal       Date:  2018-01-05       Impact factor: 8.401

3.  Progression in the LRRK2-Asssociated Parkinson Disease Population.

Authors:  Rachel Saunders-Pullman; Anat Mirelman; Roy N Alcalay; Cuiling Wang; Roberto A Ortega; Deborah Raymond; Helen Mejia-Santana; Martha Orbe-Reilly; Brooke A Johannes; Avner Thaler; Laurie Ozelius; Avi Orr-Urtreger; Karen S Marder; Nir Giladi; Susan B Bressman
Journal:  JAMA Neurol       Date:  2018-03-01       Impact factor: 18.302

4.  Deep learning for clustering of multivariate clinical patient trajectories with missing values.

Authors:  Johann de Jong; Mohammad Asif Emon; Ping Wu; Reagon Karki; Meemansa Sood; Patrice Godard; Ashar Ahmad; Henri Vrooman; Martin Hofmann-Apitius; Holger Fröhlich
Journal:  Gigascience       Date:  2019-11-01       Impact factor: 6.524

Review 5.  The role of neuroimaging in Parkinson's disease.

Authors:  Natasha S R Bidesi; Ida Vang Andersen; Albert D Windhorst; Vladimir Shalgunov; Matthias M Herth
Journal:  J Neurochem       Date:  2021-10-03       Impact factor: 5.546

6.  Spinal Lewy body pathology in older adults without an antemortem diagnosis of Parkinson's disease.

Authors:  Aron S Buchman; Sukriti Nag; Sue E Leurgans; Jared Miller; Veronique G J M VanderHorst; David A Bennett; Julie A Schneider
Journal:  Brain Pathol       Date:  2017-10-27       Impact factor: 6.508

7.  Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity.

Authors:  Emily J Hill; C Grant Mangleburg; Isabel Alfradique-Dunham; Brittany Ripperger; Amanda Stillwell; Hiba Saade; Sindhu Rao; Oluwafunmiso Fagbongbe; Rainer von Coelln; Arjun Tarakad; Christine Hunter; Robert J Dawe; Joseph Jankovic; Lisa M Shulman; Aron S Buchman; Joshua M Shulman
Journal:  Parkinsonism Relat Disord       Date:  2021-02-10       Impact factor: 4.891

8.  Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes.

Authors:  Isabel Alfradique-Dunham; Rami Al-Ouran; Rainer von Coelln; Cornelis Blauwendraat; Emily Hill; Lan Luo; Amanda Stillwell; Emily Young; Anita Kaw; Manuela Tan; Calwing Liao; Dena Hernandez; Lasse Pihlstrom; Donald Grosset; Lisa M Shulman; Zhandong Liu; Guy A Rouleau; Mike Nalls; Andrew B Singleton; Huw Morris; Joseph Jankovic; Joshua M Shulman
Journal:  Neurol Genet       Date:  2021-01-28

9.  The commercial genetic testing landscape for Parkinson's disease.

Authors:  Lola Cook; Jeanine Schulze; Jennifer Verbrugge; James C Beck; Karen S Marder; Rachel Saunders-Pullman; Christine Klein; Anna Naito; Roy N Alcalay
Journal:  Parkinsonism Relat Disord       Date:  2021-10-19       Impact factor: 4.891

10.  Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers.

Authors:  Jared Thomas Hinkle; Kate Perepezko; Catherine C Bakker; Martinus P G Broen; Kathleen Chin; Ted M Dawson; Vanessa Johnson; Zoltan Mari; Cherie L Marvel; Kelly A Mills; Alexander Pantelyat; Olga Pletnikova; Liana S Rosenthal; Melissa D Shepard; Daniel A Stevens; Juan C Troncoso; Jiangxia Wang; Gregory M Pontone
Journal:  Mov Disord Clin Pract       Date:  2017-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.